Take steps to keep you and your family insured in case you’re no longer eligible for pandemic-related health care coverage. During the COVID-19 pandemic, people who no longer were eligible for Medicaid or the Children’s Health Insurance Program (CHIP) could keep their coverage. However, continuous CHIP coverage ends in May, and some states will start to disenroll people from Medicaid on April 1.
Participants in the Pulmonary Hypertension Association (PHA)’s first Advocacy Town Hall selected PHA’s top legislative priority for this year: protecting patient access to charitable assistance. The town hall also focused on another legislative priority: oxygen access.
The Pulmonary Hypertension Association is accepting applications for a new grant to support junior pulmonary hypertension researchers. Apply now, or spread the word about PHA’s Early Career Mentored Scientist Award. The one-year grant covers up to $65,000 for PH-related research projects that have been favorably reviewed but not funded by the National Institutes of Health. Apply by March 20.
Specialty pharmacies that distribute pulmonary hypertension (PH) medications are currently reaching out to patients and health care professionals to provide an urgent update about specific lots of CADD infusion systems. If you receive a call or email from your specialty pharmacy about this issue, please respond as soon as possible. PHA is actively monitoring this situation and will provide additional information as it becomes available.
Since becoming aware of disruptions in CADD-MS3 (MS3) access earlier this year, the Pulmonary Hypertension Association (PHA) has been meeting with stakeholders and advocating on behalf of health care professionals and patients. To date, PHA has met with ICU Medical (device manufacturer); United Therapeutics Corporation (Remodulin); Liquidia (generic treprostinil); and Accredo Specialty Pharmacy. The
Since becoming aware of disruptions in CADD-MS3 access earlier this year, the Pulmonary Hypertension Association (PHA) has been advocating for prompt access to treprostinil. Supply chain disruptions have affected supply of the pump’s LCD screen and slowed the manufacturer’s ability to service pumps for reuse. As a result, specialty pharmacies halted new patient starts on the MS3, and eligible patients may have been shifted to a delivery system for Remodulin.
Need CME credit? Check out PHA Online University courses on various diseases associated with pulmonary hypertension. Learn more.
The Pulmonary Hypertension Association is accepting applications for the 2023 PHPN Symposium Committee, as well as for the position of 2023 PHPN Symposium Vice-Chair. The PHPN Symposium Committee participates in planning the professional education activities for PHA’s biennial PHPN Symposium. Learn more and apply.
The Pulmonary Hypertension Association is accepting applications for the 2023 PHPN Symposium Committee, as well as for the position of 2023 PHPN Symposium Vice-Chair. The PHPN Symposium Committee participates in planning the professional education activities for PHA’s biennial PHPN Symposium. Learn more and apply.
The Pulmonary Hypertension Association is launching a new grant opportunity to support pediatric pulmonary hypertension research. The award will support a pilot study for one year, up to $65,000 a year, that would provide foundational research for a larger study and support additional grant submissions. Learn more.
